All questions
Pharmacology: Darzalex (daratumumab) in multiple myeloma 4 questions · 3 sources
Questions that apply to every indication of Darzalex are on Darzalex (daratumumab), all indications .
Mechanism How does Darzalex (daratumumab) work in multiple myeloma (mechanism of action)? What does the hyaluronidase in Darzalex Faspro do? Note: The Support & Resources page also gives a half-life of 0.5 days for recombinant hyaluronidase, and the Dosing and Administration Guide gives a half-life in skin of less than 30 minutes; the Prescribing Information gives the 0.5-day half-life for hyaluronan.
Pharmacokinetics What is the half-life of Darzalex (daratumumab)? Note: The first passage is from the DARZALEX (intravenous) Prescribing Information; the second is from the DARZALEX FASPRO Prescribing Information.
Components What are the inactive ingredients in Darzalex and Darzalex Faspro? “DARZALEX® (daratumumab) injection is supplied as a colorless to pale yellow
preservative-free solution for intravenous use in a single-dose vial. The pH
is 5.5.
Each DARZALEX 20 mL single-dose vial contains (NDC 57894-502-20) 400 mg
daratumumab, glacial acetic acid (3.7 mg), mannitol (510 mg), polysorbate 20
(8 mg), sodium acetate trihydrate (59.3 mg), sodium chloride (70.1 mg), and
Water for Injection, USP.
Each DARZALEX 5 mL single-dose vial contains (NDC 57894-502-05) 100 mg
daratumumab, glacial acetic acid (0.9 mg), mannitol (127.5 mg), polysorbate 20
(2 mg), sodium acetate trihydrate (14.8 mg), sodium chloride (17.5 mg), and
Water for Injection, USP.
Each DARZALEX 20 mL single-dose vial contains (NDC 57894-505-20) 400 mg
daratumumab, L-histidine (7 mg), L-histidine hydrochloride monohydrate
(32.6 mg), L-methionine (20 mg), polysorbate 20 (8 mg), sorbitol (1093 mg), and
Water for Injection, USP.
Each DARZALEX 5 mL single-dose vial contains (NDC 57894-505-05) 100 mg
daratumumab, L-histidine (1.8 mg), L-histidine hydrochloride monohydrate
(8.2 mg), L-methionine (5 mg), polysorbate 20 (2 mg), sorbitol (273.3 mg), and
Water for Injection, USP.” (opens the source at this quote in a new tab) Copy Flag
“DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) injection is a
sterile, preservative-free, colorless to yellow, and clear to opalescent solution
supplied in a single-dose vial for subcutaneous administration.
Each DARZALEX FASPRO 15 mL single-dose vial contains 1,800 mg of
daratumumab and 30,000 units of hyaluronidase, L-histidine (4.9 mg),
L-histidine hydrochloride monohydrate (18.4 mg), L-methionine (13.5 mg),
polysorbate 20 (6 mg), sorbitol (735.1 mg), and Water for Injection, USP.” (opens the source at this quote in a new tab) Copy Flag
Note: Both passages are from the Description section of the Prescribing Information: the first for DARZALEX (intravenous), the second for DARZALEX FASPRO.